Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 27, 2013

Adaptive, Biogen Idec Ink Immunological Biomarkers Agreement

  • Adaptive Biotechnologies and Biogen Idec are together searching for immunological biomarkers for difficult-to-treat autoimmune diseases, the firms said. Financial terms were not disclosed.

    Under the terms of the agreement, the firms will use Adaptive's immune profiling assay immunoSEQ to characterize samples from patients with autoimmune disorders with high unmet needs. The assay uses next-generation sequencing to characterize T and B cell receptors for the purpose of monitoring patient immune status.

    "We are delighted to collaborate with Biogen Idec to help further characterize the immune status of patients with autoimmune diseases who are often quite heterogeneous and therefore, difficult to treat without a more personalized approach," Adaptive CEO Chad Robinssaid in a statement. "Partnering with Biogen Idec fits squarely with Adaptive's dual commitment to a deeper understanding of complex diseases as well as to finding better means to treat them.”



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »